



BXTB 3083 (BSPI-5319L CONT)

PATENT

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Olson, et al.
Application No. 09/654,688
Filed September 5, 2000
Confirmation No. 8203
Entitled HEMOGLOBIN MUTANTS THAT REDUCE HEME LOSS

COMMISSIONER OF PATENTS AND TRADEMARKS
WASHINGTON, D.C. 20231

CERTIFICATE UNDER 37 CFR 3.73(b)

William Marsh Rice University, a Texas corporation, certifies that it is the assignee in the patent application identified above by virtue of an assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel 010629, Frame 0729.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date

Daryl S. Boudreaux
Daryl S. Boudreaux
Director
Office of Technology Transfer
William Marsh Rice University